Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
PXT3003 therapy acting on Pmp22 overexpression and downstream ...
Synergistic PXT3003 therapy uncouples neuromuscular function from ...
PXT3003 Aims to Become First Approved Therapeutic for Charcot-Marie ...
[PDF] Early short-term PXT3003 combinational therapy delays disease ...
SESSION 9 Pharnext PXT3003 dans la CMT1A, analyse de l'essai de phase 3 ...
Figure 2 from Early short-term PXT3003 combinational therapy delays ...
Early short-term PXT3003 combinational therapy delays disease onset in ...
PXT3003 for Patients With CMT1A Shows Sustained Safety, Benefits
(PDF) A double-blind, placebo-controlled, randomized trial of PXT3003 ...
A double-blind, placebo-controlled, randomized trial of PXT3003 for the ...
Pivotal Phase 3 Trial of PXT3003 to Begin CMT1A Patient Enrollment Soon
(PDF) Early short-term PXT3003 combinational therapy delays disease ...
CMT1A Investigative Therapy PXT3003 Focus of Pharnext's Phase 3 Trials
Charcot-Marie-Tooth Disease - Pharnext Announces PXT3003 for the ...
(PDF) Synergistic PXT3003 therapy uncouples neuromuscular function from ...
Pharnext: Data from First Phase III Clinical Study of PXT3003 in ...
Pharnext working toward applications for PXT3003 approval
Petition to request Pharnext to make PXT3003 available through FDA ...
Daily oral treatment of CMT1A rats with PXT3003 down-regulates Pmp22 ...
Pharnext announces first patient enrolled in phase 3 study of PXT3003
Baseline Analysis of PXT3003 Phase 2 Data Reveals Two Blood Early ...
Daily oral treatment of CMT1A rats with PXT3003 improves myelination ...
Charcot - High-dose PXT3003 continues to show long-term safety and ...
CMT1A : de nouveaux résultats cliniques du PXT3003 | AFM Téléthon
Charcot-Marie-Tooth 1A drug PXT3003 FAILED (рус.субтитры) - YouTube
Pharnext — Funding headroom to support PXT3003 progress - Edison Group
Response to PXT3003 on clinical scales (Full Analysis Set, n = 80 ...
Pharnext Enrolls 1st Patient in CMT1A PREMIER Trial Testing PXT3003
Response to PXT3003 on efficacy outcomes in treatment groups, with ...
Trattamento CMT1A con PXT3003 di Pharnext: Prospettive per il 2020
First Patient Enrolled in Europe in PREMIER Trial of PXT3003 for CMT1A
CMT1A Treatment PXT3003 Shows Promise in Extension Trial, Study Says
Petition · Urge Pharnext to Make PXT3003 Accessible through FDA ...
Funding Supports Pharnext's Planned Phase 3 Trial of PXT3003 for CMT1A
Pharnext Announces PXT3003 was Granted Priority Review by the China ...
Pharnext Announces Positive Topline Results from Pivotal Phase 3 Trial ...
Pharnext: New Data from the Open-Label PLEO-CMT-FU Trial Shows ...
Full article: Charcot-Marie-Tooth disease: a review of clinical ...
CMT1A Study Finds PXT3003's Components Together Improve Outcomes
An exploratory randomised double-blind and placebo-controlled phase 2 ...
Pharnext — New efficacy and new indications from old drugs - Edison Group
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of ...
Actualizaciones sobre estudio PXT3003, tratamiento para Charcot-Marie ...
(PDF) AN EXPERIMENTAL TRIAL OF AN EARLY ONSET SHORT-TERM TREATMENT WITH ...
Therapeutic Development In Charcot Marie Tooth Type 1 Disease – EKVZCX
(PDF) An exploratory randomised double-blind and placebo-controlled ...
Pharnext on Twitter: "[Press Release] @Pharnext Announces Encouraging ...
#pxt3003 #charcotmarietooth | PHARNEXT
Charcot-Marie-Tooth Disease - CMT1A Clinical Trial Update: Pharnext ...
샤르코-마리-투스병 CMT 완치에 한 걸음 더? 기존 약을 바꿔서 치료제로 쓰는 ‘약물 재창출’의 기적 (PXT3003, 고보레 ...
희귀질환 _ 샤르코-마리-투스 병(Charcot-Marie-Tooth disease) : 네이버 블로그
Taille, part et prévisions du marché de la maladie de Charcot-Marie ...
Doença de Charcot-Marie-Tooth, foco diário – ABN – Academia Brasileira ...
(PDF) The Current State of Charcot–Marie–Tooth Disease Treatment
Doença de Charcot-Marie-Tooth – ABN – Academia Brasileira de Neurologia
@Pharnext announces database lock for #PXT3003 pivotal Phase 3 clinical ...
PXT3003进入优先审评，注射用丹参多酚酸新进山东医保
PHARNEXT : Pharnext annonce son intention de préparer des dossiers d ...
Baclofen, Naltrexone, and Sorbitol All Contribute to the Efficacy of ...
BCL, NTX, SRB and their mix (PXT3003) down-regulate Pmp22 mRNA ...
Polytherapy with a combination of three repurposed drugs (PXT3003) down ...
Run 4 CMT: Update Pharnext PXT 3003 Clinical Trial
Mechanisms and Treatments in Demyelinating CMT - Neurotherapeutics
PXT3003项目III期临床进展顺利，生物药布局值得期待
Maladie de Charcot-Marie-Tooth - dans la Avancées - Myobase
Uso de IA para la reutilización de fármacos en la enfermedad de Charcot ...
(PDF) Polytherapy with a combination of three repurposed drugs (PXT3003 ...
PHARNEXT appoints Gilbert Wagener, MD, PhD as Chief Medical Officer. He ...
【海外案例】旧药新用解决老年痴呆症 – Pharnext独具一格的药物研发智慧-动脉网
Raccolta di link interessanti sulla Charcot-Marie-Tooth | Linktree
-Targeting CMT1A. Schematic representation of currently tested drugs to ...
BCL, NTX, SRB and their mix (PXT3003) improve myelination in DRG ...
Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept ...
Pharnext bondit alors qu'un accord de licence se précise pour son ...
Charcot-Marie-Tooth: Όχι, δεν είναι νόσος των δοντιών! (Και γιατί ...
罕见病信息网
